Structural insights into SARS-CoV-2 proteins

Arya, Rimanshee; Kumari, Shweta; Pandey, Bharati; Mistry, Hiral; Bihani, Subhash C.; Das, Amit Kumar; Prashar, Vishal; Gupta, Gagan D.; Panicker, Lata; Kumar, Mukesh

doi:10.1016/j.jmb.2020.11.024

Cited by 279 publications

(310 citation statements)

References 164 publications

Supporting

Mentioning

277

Contrasting

Unclassified

Order By: Relevance

“…Two mutations located in Spike protein (G75V and C1247F) are present in all Polish mink virus isolates. G75V mutation is localised in the NTD domain and could be responsible for interaction with host receptors or stabilising Spike protein in a constrained prefusion state (Arya et al, 2021). Non-other sequences of SARS-CoV-2 deposited to date in GISAID possess these two mutations simultaneously (Shu and McCauley, 2017).…”

Section: Discussionmentioning

confidence: 99%

Detection and molecular characterisation of SARS-CoV-2 in farmed mink (Neovision vision) in Poland

Rąbalski

Kosinski

Smura

et al. 2020

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 is the aetiological agent of COVID-19 disease and has been spreading worldwide since December 2019. The virus has been shown to infect different animal species under experimental conditions. Also, minks have been found to be susceptible to SARS-CoV-2 infection in fur farms in Europe and the USA. Here we investigated 91 individual minks from a farm located in Northern Poland. Using RT-PCR, antigen detection and NGS, we confirmed 15 animals positive for SARS-CoV-2. The result was verified by sequencing of full viral genomes, confirming SARS-CoV-2 infection in Polish mink. Country-scale monitoring conducted by veterinary inspection so far has not detected the presence of SARS-CoV-2 on other mink farms. Taking into consideration that Poland has a high level of positive diagnostic tests among its population, there is a high risk that more Polish mink farms become a source for SARS-CoV-2. Findings reported here and from other fur producing countries urge the assessment of SARS-CoV-2 prevalence in animals bred in Polish fur farms.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection and molecular characterisation of SARS-CoV-2 in farmed mink (Neovision vision) in Poland

Rąbalski

Kosinski

Smura

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The interaction between the S protein and ACE2 receptor allows the attachment of the virus to the host cell (1). After that, the entry can be achieved by endocytosis (2) or by fusion of the viral and cellular membranes (3). Once inside, the viral RNA begins to be translated for producing the 1a and 1ab proteins (4).…”

Section: Infection Of Sars-cov-2mentioning

confidence: 99%

How glycobiology can help us treat and beat the COVID-19 pandemic

Lardone¹,

Garay²,

Parodi³

et al. 2021

Journal of Biological Chemistry

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge during the last months of 2019, expanding throughout the world as a highly transmissible infectious illness designated as COVID-19. Vaccines have now appeared, but the challenges in producing sufficient material and distributing them around the world means that effective treatments to limit infection and improve recovery are still urgently needed. This review is focused on the relevance of different glycobiological molecules that could potentially serve as or inspire therapeutic tools during SARS-CoV-2 infection. As such, we highlight the glycobiology of the SARS-CoV-2 infection process, where glycans on viral proteins and on host glycosaminoglycans have critical roles in efficient infection. We also take notice of the glycan-binding proteins involved in the infective capacity of virus and in human defense. In addition, we critically evaluate the glycobiological contribution of candidate drugs for COVID-19 therapy such as glycans for vaccines, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and numerous glycosides, emphasizing some opportunities to repurpose FDA-approved drugs. For the next generation drugs suggested here, biotechnological engineering making new probes to block the SARS-CoV-2 infection might be based in the essential glycobiological insight on glycosyltransferases, glycans, glycan-binding proteins and glycosidases related to this pathology.

show abstract

“…ORF3a is the largest from the accessory proteins. It is a viroporin protein forming ion channels in the membrane of the host cell [ 80 ]. The protein structure contains three transmembrane helices and a cytosolic domain.…”

Section: Accessory Proteinsmentioning

confidence: 99%

“…The channels are formed by the six dimer helices with their residues placed inside. Thus the channels are capable of cations conducting, preferentially Ca2+ and K+ [ 80 ]. The ORF3a protein blocks mechanism of autophagy [ 76 ], causes damage of lysosomes resulting in their improper functioning [ 76 ], is implicated in the inflammasomes activation which can influence the cytokine storm development.…”

Section: Accessory Proteinsmentioning

confidence: 99%

“…ORF8 contains 121 amino acids, and is the second-largest accessory protein encoded by the genome of SARS-CoV-2 [ 75 ]. The main components of the protein structure are: the sequence of N-terminal signal for import to endoplasmic reticulum and a core of β-strand which is similar to the (Ig)-like fold of immunoglobulin [ 75 , 80 ]. ORF8 does not contain the C terminal transmembrane domain.…”

Section: Accessory Proteinsmentioning

confidence: 99%

See 1 more Smart Citation

Reducing SARS-CoV-2 pathological protein activity with small molecules

Pluskota-Karwatka

Hoffmann

Barciszewski

2021

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

Coronaviruses are dangerous human and animal pathogens. The newly identified coronavirus SARS-CoV-2 is the causative agent of COVID-19 outbreak, which is a real threat to human health and life. The world has been struggling with this epidemic for about a year, yet there are still no targeted drugs and effective treatments are very limited. Due to the long process of developing new drugs, reposition of existing ones is one of the best ways to deal with an epidemic of emergency infectious diseases. Among the existing drugs there are candidates which are potentially able to inhibit the SARS-CoV-2 replication, and thus infection with the virus. Some therapeutics target several proteins, and many diseases share molecular paths. In such cases, the use of existing pharmaceuticals for more than one purposes can reduce the time needed to design new drugs. The aim of this review was to analyse the key targets of viral infection and potential drugs acting on them, as well as to discuss various strategies and therapeutic approaches, including the possible use of natural products. We highlight the approach based on increasing the involvement of human deaminases, particularly APOBEC deaminases in editing of SARS-CoV-2 RNA. This can reduce the cytosine content in the viral genome leading to the loss of its integrity. We also indicate the nucleic acid technologies as potential approaches for COVID-19 treatment. Among numerous promising natural products, we point out curcumin and cannabidiol as good candidates for being anti-SARS-CoV-2 agents.

show abstract

Structural insights into SARS-CoV-2 proteins

Cited by 279 publications

References 164 publications

Detection and molecular characterisation of SARS-CoV-2 in farmed mink (Neovision vision) in Poland

Detection and molecular characterisation of SARS-CoV-2 in farmed mink (Neovision vision) in Poland

How glycobiology can help us treat and beat the COVID-19 pandemic

Reducing SARS-CoV-2 pathological protein activity with small molecules

Contact Info

Product

Resources

About